Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.
Yiqing YangLin CaoHongying GaoYue WuYaxin WangFang FangTianlong LanZhiyong LouYu RaoPublished in: Journal of medicinal chemistry (2019)
Viral infections are increasing and probably long-lasting global risks. In this study, a chemical library was exploited by phenotypic screening to discover new antiviral inhibitors. After optimizations from hit to lead, a novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others. The mechanism of action and potential targets of RYL-634 were further explored by the combination of activity-based protein profiling and other techniques. Finally, human dihydroorotate dehydrogenase was validated as the major target of RYL-634. We did not observe any mutant resistance under our pressure selections with RYL-634, and it had a strong synergistic effect with some Food and Drug Administration-approved drugs. Hence, there is great potential for developing new broad-spectrum antivirals based on RYL-634.
Keyphrases
- zika virus
- dengue virus
- human immunodeficiency virus
- hepatitis c virus
- small molecule
- drug administration
- human health
- aedes aegypti
- respiratory syncytial virus
- protein protein
- antiretroviral therapy
- endothelial cells
- hiv infected
- risk assessment
- sars cov
- hiv positive
- induced pluripotent stem cells
- anti inflammatory
- amino acid